Pelvic floor disorders represent a large and growing clinical need. Published U.S. estimates indicate that roughly one quarter of women experience at least one pelvic floor disorder, and forecast models project that the number of affected women could rise from 28.1 million in 2010 to 43.8 million by 2050. In that context, vaginal pessaries remain an important non-surgical management option for pelvic organ support.
For manufacturers, however, a vaginal pessary is not simply a molded silicone product. In the United States, the FDA classifies the vaginal pessary as a Class II medical device under 21 CFR 884.3575, using product code HHW and a 510(k) premarket pathway. The FDA classification record also indicates that this device type is not GMP-exempt, is Medical Device Reporting eligible, and is not classified as implanted or life-sustaining.
FDA regulatory snapshot
The core FDA classification points for vaginal pessaries are summarized below.
| Regulatory item | FDA status |
|---|---|
| Device type | Vaginal pessary |
| Regulation number | 21 CFR 884.3575 |
| Product code | HHW |
| Device class | Class II |
| Premarket route | 510(k) |
| Medical specialty panel | Obstetrics/Gynecology |
| GMP exempt | No |
| MDR eligible | Yes |
| Implanted device | No |
| Life-sustain/life-support | No |
What the Class II designation means in practice
Class II status means manufacturers should generally expect to pursue a 510(k) clearance based on substantial equivalence to a legally marketed predicate device, rather than relying on simple registration and listing alone. FDA states that the 510(k) program includes Traditional, Special, and Abbreviated submission types, with the Traditional 510(k) available in all circumstances and Special or Abbreviated pathways used only when their eligibility conditions are met.
This also means that changes to the device should be treated carefully. FDA states that a new 510(k) is required when an existing device is significantly modified in design, components, method of manufacture, or intended use in a way that could significantly affect safety or effectiveness, or when the intended use changes materially. For a pessary, that can make geometry changes, material changes, removal-feature changes, or manufacturing-process changes more consequential than they may first appear.
Submission expectations: eSTAR is now the norm
FDA’s current policy is clear: all 510(k) submissions must be submitted electronically using eSTAR unless exempted. FDA’s eSTAR page states that this requirement has applied to 510(k) submissions since October 1, 2023, and that eSTAR is intended to standardize content and improve submission quality. For manufacturers entering the U.S. market, that means regulatory readiness now depends not only on test data, but also on the ability to assemble a structured and complete submission file from the outset.
For foreign manufacturers, establishment compliance is also part of market access. FDA states that any foreign establishment involved in manufacturing a device imported into the United States must identify a U.S. Agent as part of the establishment registration process.
QMSR has raised the importance of quality-system alignment
As of February 2, 2026, FDA’s device quality framework is the Quality Management System Regulation (QMSR) under 21 CFR Part 820, which incorporates ISO 13485:2016 by reference. FDA also states that it has shifted inspections to the updated compliance program tied to QMSR. For manufacturers of vaginal pessaries, this matters because the category is expressly not GMP-exempt, so quality-system maturity is part of the regulatory foundation rather than an optional enhancement.
In practical terms, that raises the bar on document control, design controls, supplier control, process validation, complaint handling, CAPA, and change management. For a device that is inserted, removed, cleaned, and reused in a sensitive anatomical environment, manufacturing consistency is not just an operational concern; it is directly relevant to safety, effectiveness, and postmarket defensibility.
Silicone is common, but material selection is only part of the regulatory story
Silicone is widely used in pessary products, but FDA does not evaluate safety based only on raw-material marketing language. FDA’s biocompatibility guidance states that the Agency assesses the finished device in its final form, not merely the base material, and that the evaluation should consider not only component materials but also processing, manufacturing methods, sterilization if applicable, and residuals from manufacturing aids. FDA’s current framework is based on its guidance on ISO 10993-1 and is explicitly risk-based.
That distinction is critical for manufacturers. A silicone pessary may still require a tailored biological evaluation strategy based on contact type, duration of contact, manufacturing residues, pigments, surface treatment, packaging, cleaning instructions, and whether the device is reusable. In other words, “medical-grade silicone” can support a program, but it does not replace finished-device evidence.
What recent FDA-cleared products suggest about evidence expectations
A useful public example is K231786, the FDA-cleared Gynethotics™ Pessary, a Traditional 510(k) cleared in March 2024 under product code HHW. Public FDA materials for that submission show that modern pessary reviews can involve more than simple dimensional comparison. The public record reflects a formal 510(k) pathway and a cleared product within this exact device category.
For manufacturers, the lesson is straightforward: even when a pessary appears mechanically simple, FDA may still expect evidence aligned to actual patient contact, intended use, cleaning and packaging claims, and finished-device risk. That is especially true when a device family spans multiple shapes, sizes, or support configurations.
Postmarket signals: what public FDA data suggests manufacturers should watch
FDA’s Total Product Life Cycle database integrates premarket and postmarket data by product code, including adverse-event information derived from MAUDE. For product code HHW, the public TPLC record shows recurring device-problem categories such as material separation, break, component missing, difficult to remove, and material too rigid or stiff. The same FDA disclaimer also states that TPLC counts may change as source databases are refreshed and that device-problem counts do not necessarily equal report counts because one report may contain multiple device-problem codes.
That makes these data useful for risk prioritization, not for incidence claims. FDA states separately that MAUDE/MDR data should not be used to calculate event rates, compare event frequency across devices, or prove causality, because the system is passive and incomplete by design. Manufacturers should therefore use the public data directionally: to guide design FMEA, complaint trending, durability testing, user-handling analysis, and corrective-action planning.
What manufacturers should prepare before starting a U.S. pessary project
A manufacturer planning a U.S. pessary program should be ready in five areas.
First, it should have a clear predicate strategy, a stable intended use statement, and a well-defined device-family rationale. That is the foundation of a defensible 510(k).
Second, it should maintain robust design and change-control documentation, because design, material, or process changes may trigger the need for a new 510(k).
Third, it should have a finished-device biocompatibility strategy aligned with FDA’s ISO 10993-1 framework, rather than relying solely on raw-material declarations.
Fourth, it should be prepared to support verification and validation for the actual claims being made, including, where relevant, packaging, cleaning, shelf life, usability, and durability. FDA’s current premarket framework is structured around complete, evidence-backed submissions, not partial technical narratives.
Fifth, it should operate inside a QMSR-ready quality system capable of handling complaints, MDR assessment, CAPA, and inspection scrutiny. For this device class, that is not a secondary issue.
Manufacturer checklist
Before freezing design and tooling, manufacturers should be able to answer the following questions:
- Does the intended use align closely with an available predicate under product code HHW?
- Could any planned material, design, or process changes require a new 510(k)?
- Has biocompatibility been planned for the finished device, not just the silicone base material?
- Are labeling, cleaning, packaging, and durability claims supported by validation data?
- Is the manufacturing site ready for QMSR-based quality-system expectations?
- If the manufacturer is outside the U.S., has a U.S. Agent and registration/listing plan been established?
FAQ
Is a vaginal pessary a Class I device?
No. FDA classifies the vaginal pessary as a Class II device under 21 CFR 884.3575, product code HHW.
Does a pessary typically require a 510(k)?
Yes. FDA’s classification database lists 510(k) as the submission type for this device category.
Is ISO 13485 alone enough for U.S. compliance?
No. ISO 13485 is highly relevant because FDA’s QMSR now incorporates it by reference, but U.S. compliance still involves FDA-specific regulatory obligations such as classification, 510(k) clearance where required, registration and listing, complaint handling, and MDR responsibilities.
Can manufacturers use MAUDE data to claim low complaint rates or compare products?
No. FDA states that MDR/MAUDE data should not be used to calculate event rates, compare devices, or establish causality.
Conclusion
The FDA classification of vaginal pessaries is simple in form but demanding in execution. The category is clearly defined as Class II, product code HHW, under 21 CFR 884.3575 with a 510(k) pathway. What separates a viable manufacturer from a risky one is not the classification label itself, but the ability to translate that label into predicate discipline, finished-device biocompatibility logic, QMSR-ready manufacturing, controlled design changes, and a serious postmarket quality system.
This article is for general informational purposes only and should not be treated as legal or regulatory advice. Manufacturers should evaluate their device strategy, testing plan, and submission pathway with qualified regulatory professionals before entering the U.S. market.